HW091077 / Humanwell Healthcare - LARVOL DELTA

A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC). (clinicaltrials.gov) - P2 | N=180 | Not yet recruiting | Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

New P2 trial • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

Development of a P2X3 receptor antagonist derived from eliapixant with improved properties for the treatment of chronic cough. (PubMed, Eur J Med Chem) - "The P2X3 receptor is an ATP-activated ion channel primarily expressed on peripheral sensory neurons. Our strategy described herein are maintaining a moderate selectivity between P2X3 and P2X2/3 receptors and replacing the metabolically labile motif with 3-methylbutan-2-ol. These discovery efforts lead to the identification of HW091077, a P2X3 receptor antagonist with an optimal balance of potency, selectivity, PK and metabolic properties that has advanced into clinical trials for the treatment of chronic cough."

Journal • Chronic Cough • Cough • Hepatology • Liver Failure • Pulmonary Disease • Respiratory Diseases